Dashboard
Manage Tickers

AUPH


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

rbc-capital-downgrades-aurinia-pharmaceuticals-to-sector-perform-raises-price-target-to-15
RBC Capital Downgrades Aurinia Pharmaceuti...
11/05/2025 12:36:31

RBC Capital analyst Douglas Miehm downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) from Outperform to Sector Perform and rai...

earnings-scheduled-for-november-4-2025
Earnings Scheduled For November 4, 2025
11/04/2025 11:12:08

aurinia-pharmaceuticals-raises-fy2025-sales-guidance-from-260000m-270000m-to-275000m-280000m-vs-270478m-est
Aurinia Pharmaceuticals Raises FY2025 Sale...
11/04/2025 11:01:14

Aurinia Pharmaceuticals (NASDAQ:AUPH) raises FY2025 sales outlook from $260.000 million-$270.000 million to $275.000 million-$2...

aurinia-pharmaceuticals-q3-eps-023-beats-016-estimate-sales-73468m-beat-67418m-estimate
Aurinia Pharmaceuticals Q3 EPS $0.23 Beats...
11/04/2025 11:00:46

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate ...

a-peek-at-aurinia-pharmaceuticalss-future-earnings
A Peek at Aurinia Pharmaceuticals's Future...
11/03/2025 21:01:58

fda-drug-chief-george-tidmarsh-resigns-after-allegations-of-power-misuse
FDA Drug Chief George Tidmarsh Resigns Aft...
11/03/2025 11:58:38

FDA drug center head George Tidmarsh resigned after accusations of misusing power to harm a former business associate. He denie...

aurinia-pharmaceuticals-to-present-new-lupkynis-data-on-lupus-nephritis-at-acr-and-asn-conferences
Aurinia Pharmaceuticals to Present New LUP...
10/15/2025 10:02:53

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that five posters will be presented in collaboration with independen...

reported-earlier-aurinia-responds-to-retracted-linkedin-post-stands-behind-full-fda-approval-of-lupkynis-in-lupus-nephritis
Reported Earlier, Aurinia Responds To Retr...
09/30/2025 06:33:12

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
09/29/2025 21:06:06

Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's...

rbc-capital-maintains-outperform-on-aurinia-pharmaceuticals-raises-price-target-to-9
RBC Capital Maintains Outperform on Aurini...
08/01/2025 15:12:00

RBC Capital analyst Douglas Miehm maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Outperform and raises the price tar...

aurinia-pharmaceuticals-raises-fy2025-sales-guidance-from-25000m-26000m-to-26000m-27000m-vs-25852m-est
Aurinia Pharmaceuticals Raises FY2025 Sale...
07/31/2025 10:01:44

Aurinia Pharmaceuticals (NASDAQ:AUPH) raises FY2025 sales outlook from $250.00 million-$260.00 million to $260.00 million-$270....

aurinia-pharmaceuticals-q2-eps-016-beats-014-estimate-sales-7001m-beat-6425m-estimate
Aurinia Pharmaceuticals Q2 EPS $0.16 Beats...
07/31/2025 10:00:40

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate ...

Core News & Articles
Earnings Scheduled For July 31, 2025
07/31/2025 08:32:50

hc-wainwright--co-assumes-aurinia-pharmaceuticals-at-buy-announces-price-target-of-17
HC Wainwright & Co. Assumes Aurinia Pharma...
07/30/2025 11:12:41

HC Wainwright & Co. analyst Arthur He assumes Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy rating and announces Pric...

aurinia-pharmaceuticals-announces-results-from-a-phase-1-single-ascending-dose-study-of-aritinercept-aur200-doses-of-5-mg-25-mg-75-mg-150-mg-225-mg-and-300-mg-and-placebo-administered-by-subcutaneous-injection-in-61-healthy-subjects
Aurinia Pharmaceuticals Announces Results ...
06/30/2025 10:12:31

Aritinercept was well tolerated at all dose levels tested. There were no treatment-related Grade ≥3 adverse events, there were ...

us-stocks-likely-to-open-on-a-mixed-note-nothing-good-happens-above-a-5-yield-says-expert
US Stocks Likely To Open On A Mixed Note: ...
05/23/2025 10:15:19

U.S. stock futures were fluctuating on Friday after a mixed close on Thursday. Futures of benchmark indices were mixed in prema...

aurinias-aurora-1-analysis-links-ultra-low-proteinuria-with-favorable-lipidomic-profiles-in-lupus-nephritis
Aurinia's AURORA 1 Analysis Links Ultra-Lo...
05/22/2025 10:08:06

aurinia-pharma-swings-into-profit-as-q1-sales-jumps-24-sticks-to-guidance
Aurinia Pharma Swings Into Profit As Q1 Sa...
05/12/2025 16:56:52

Aurinia posts Q1 profit and 25% LUPKYNIS sales growth, reports $62.47 million revenue, and reaffirms full-year guidance.

aurinia-pharmaceuticals-affirms-fy2025-sales-guidance-of-25000m-26000m-vs-25787m-est
Aurinia Pharmaceuticals Affirms FY2025 Sal...
05/12/2025 10:03:04

Aurinia Pharmaceuticals (NASDAQ:AUPH) affirms FY2025 sales outlook from $250.00 million-$260.00 million to $250.00 million-$260...

aurinia-pharmaceuticals-q1-eps-016-beats-010-estimate-sales-6247m-beat-6154m-estimate
Aurinia Pharmaceuticals Q1 EPS $0.16 Beats...
05/12/2025 10:01:20

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION